Mohammad Alhadj Ali - Concepedia

Author

Mohammad Alhadj Ali

Cardiff University ORCID

Also Known As

Alhadj Ali, Mohammad, Colin Dayan, M A Ali, M Alhadj Ali, M. Alhadj Ali, Mohammad Alhadj Ali, Mohammad Ali

Publications

594

Citations

H-Index

Concepts

All Affiliations

Cardiff University Guy's and St Thomas' NHS Foundation Trust University of Oxford King's College London Swansea University

About

Mohammad Alhadj Ali is an author at Cardiff University specializing in immunology, diabetes, and autoimmunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	64
2	Engineering	1	1	51
3	Health Sciences	1	1	13
4	Biomedical Engineering	1	1	51
5	Cell Biology	1	1	13

Mohammad Alhadj Ali

Publications

548

Citations

H-Index

Page 1

	Year	Citations
Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes Mohammad Alhadj Ali, Sefina Arif, Danijela Tatović, Science Translational Medicine	2017	211
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial PK Judge, Natalie Staplin, KJ Mayne, The Lancet Diabetes & Endocrinology	2023	88
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial Natalie Staplin, Richard Haynes, PK Judge, The Lancet Diabetes & Endocrinology	2023	74
Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes Danijela Tatović, Martina A. McAteer, J Barry, Immunotherapy Advances NanoparticlesNanotherapeuticsEngineeringImmunologyImmunotherapeutics	2022	51
INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes David B. Dunger, Sylvaine F. A. Bruggraber, Adrian Mander, Trials	2022	36
Topical steroid therapy induces pro‐tolerogenic changes in Langerhans cells in human skin Mohammad Alhadj Ali, Sally Thrower, Stephanie Hanna, Immunology	2015	22
First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes Jean Van Rampelbergh, Peter Achenbach, Richard David Leslie, BMC Medicine	2023	22
Phenotypic Analysis of Human Lymph Nodes in Subjects With New-Onset Type 1 Diabetes and Healthy Individuals by Flow Cytometry Jennie H. M. Yang, Leena Khatri, Marius Mickunas, Frontiers in Immunology	2019	20
Review: The importance of residual endogenous beta-cell preservation in type 1 diabetes Mohammad Alhadj Ali, Colin Dayan The British Journal of Diabetes ImmunologyPancreas TransplantationImmunotherapyInsulin SignalingMetabolic Syndrome	2009	13
Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol John W Gregory, Kymberley Carter, Gail Holland, BMJ Open	2021	11

Page 1